Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Down 13.5% in July

Avalo Therapeutics, Inc. (NASDAQ:AVTX) was the recipient of a large decrease in short interest during the month of July. As of July 15th, there was short interest totalling 64,800 shares, a decrease of 13.5% from the June 30th total of 74,900 shares. Based on an average daily trading volume, of 31,200 shares, the days-to-cover ratio is currently 2.1 days. Currently, 6.6% of the shares of the company are sold short.

Analyst Ratings Changes

Separately, Oppenheimer upgraded Avalo Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, April 16th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Avalo Therapeutics stock. Affinity Asset Advisors LLC purchased a new position in Avalo Therapeutics, Inc. (NASDAQ:AVTX) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 10,000 shares of the company’s stock, valued at approximately $218,000. Affinity Asset Advisors LLC owned approximately 0.97% of Avalo Therapeutics as of its most recent filing with the Securities & Exchange Commission. 87.06% of the stock is owned by institutional investors.

Avalo Therapeutics Price Performance

AVTX traded down $0.49 during trading on Tuesday, reaching $10.66. 5,480 shares of the company were exchanged, compared to its average volume of 311,442. The firm has a 50 day moving average of $12.01 and a 200 day moving average of $9.82. Avalo Therapeutics has a 52 week low of $3.95 and a 52 week high of $71.04.

Avalo Therapeutics (NASDAQ:AVTX) last issued its quarterly earnings data on Monday, May 13th. The company reported ($5.98) EPS for the quarter, missing analysts’ consensus estimates of ($1.18) by ($4.80). Avalo Therapeutics had a negative return on equity of 1,439.87% and a negative net margin of 1,639.50%. On average, research analysts forecast that Avalo Therapeutics will post -28.11 earnings per share for the current year.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.